Affiliated publications

Acknowledging ERN RARE-LIVER in a publication adds to the prominence of the network and provides a chance for fruitful collaboration. Affiliated Scientific Publications involve as major contributors at least two Health Care Providers from two different Member States within the ERN and acknowledge the ERN.

Affiliated Scientific Publications

2021

  • Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. Nicoară-Farcău O, Han G, Rudler M, Angrisani D, Monescillo A, Torres F, Casanovas G, Bosch J, Lv Y, Thabut D, Fan D, Hernández-Gea V, García-Pagán JC; Preemptive TIPS Individual Data Metanalysis, International Variceal Bleeding Study and Baveno Cooperation Study groups. Gastroenterology. 2021 Jan;160(1):193-205.e10. doi: 10.1053/j.gastro.2020.09.026.
  • Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency. van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Shneider BL, Sokal E, Grammatikopoulos T, Kadaristiana A, Jacquemin E, Spraul A, Lipiński P, Czubkowski P, Rock N, Shagrani M, Broering D, Algoufi T, Mazhar N, Nicastro E, Kelly D, Nebbia G, Arnell H, Fischler B, Hulscher JBF, Serranti D, Arikan C, Debray D, Lacaille F, Goncalves C, Hierro L, Muñoz Bartolo G, Mozer-Glassberg Y, Azaz A, Brecelj J, Dezsőfi A, Luigi Calvo P, Krebs-Schmitt D, Hartleif S, van der Woerd WL, Wang JS, Li LT, Durmaz Ö, Kerkar N, Hørby Jørgensen M, Fischer R, Jimenez-Rivera C, Alam S, Cananzi M, Laverdure N, Ferreira CT, Ordonez F, Wang H, Sency V, Kim KM, Chen HL, Carvalho E, Fabre A, Quintero Bernabeu J, Alonso EM, Sokol RJ, Suchy FJ, Loomes KM, McKiernan PJ, Rosenthal P, Turmelle Y, Rao GS, Horslen S, Kamath BM, Rogalidou M, Karnsakul WW, Hansen B, Verkade HJ. Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
  • Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis. Janik MK, Kruk B, Szczepankiewicz B, Kostrzewa K, Raszeja-Wyszomirska J, Górnicka B, Lammert F, Milkiewicz P, Krawczyk M. Liver Int. 2021 Feb;41(2):348-356. doi: 10.1111/liv.14726.
  • Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. Montali L, Gragnano A, Miglioretti M, Frigerio A, Vecchio L, Gerussi A, Cristoferi L, Ronca V, D'Amato D, O'Donnell SE, Mancuso C, Lucà M, Yagi M, Reig A, Jopson L, Pilar S, Jones D, Pares A, Mells G, Tanaka A, Carbone M, Invernizzi P. J Transl Autoimmun. 2021 Jan 6;4:100081. doi: 10.1016/j.jtauto.2021.100081.

2020

  • 2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta-analysis. Thiele M, Hugger MB, Kim Y, Rautou PE, Elkrief L, Jansen C, Verlinden W, Allegretti G, Israelsen M, Stefanescu H, Piscaglia F, García-Pagán JC, Franque S, Berzigotti A, Castera L, Jeong WK, Trebicka J, Krag A. Liver Int. 2020 Jun;40(6):1435-1446. doi: 10.1111/liv.14439. Epub 2020 Apr 8.
  • Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study. Elkrief L, Ferrusquia-Acosta J, Payancé A, Moga L, Tellez L, Praktiknjo M, Procopet B, Farcau O, De Lédinghen V, Yuldashev R, Tabchouri N, Barbier L, Dumortier J, Menahem B, Magaz M, Hernández-Gea V, Albillos A, Trebicka J, Spahr L, De Gottardi A, Plessier A, Valla D, Rubbia-Brandt L, Toso C, Bureau C, Garcia-Pagan JC, Rautou PE; for VALDIG, an EASL consortium. Hepatology. 2019 Sep;70(3):911-924. doi: 10.1002/hep.30628. Epub 2019 May 21. PMID: 30924941
  • Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. Ferrusquía-Acosta J, Bassegoda O, Turco L, Reverter E, Pellone M, Bianchini M, Pérez-Campuzano V, Ripoll E, García-Criado Á, Graupera I, García-Pagán JC, Schepis F, Senzolo M, Hernández-Gea V. J Hepatol. 2020 Oct 14:S0168-8278(20)33683-7. doi: 10.1016/j.jhep.2020.10.003.
  • Budd-Chiari syndrome. Coilly A, Potier P, Broué P, Kounis I, Valla D, Hillaire S, Lambert V, Dutheil D, Hernández-Gea V, Plessier A, Vilgrain V, Bureau C. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):420-425. doi: 10.1016/j.clinre.2020.03.015.
  • Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z.
  • Congenital portosystemic shunts: Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver. Guérin F, Franchi Abella S, McLin V, Ackermann O, Girard M, Cervoni JP, Savale L, Hernandez-Gea V, Valla D, Hillaire S, Dutheil D, Bureau C, Gonzales E, Plessier A. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):452-459. doi: 10.1016/j.clinre.2020.03.004.
  • Drug induced liver injury and vascular liver disease. Larrey D, Meunier L, Valla D, Hillaire S, Hernandez-Gea V, Dutheil D, Plessier A, Bureau C. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):471-479. doi: 10.1016/j.clinre.2020.03.020.
  • Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, Gerussi A, Saffioti F, Thorburn D, Nilsson E, Larsson G, Moum BA, van Munster KN, Ponsioen CY, Levy C, Nogueira NF, Bowlus CL, Gotlieb N, Shibolet O, Lynch KD, Chapman RW, Rupp C, Vesterhus M, Jørgensen KK, Rorsman F, Schramm C, Sabino J, Vermeire S, Zago A, Cazzagon N, Marschall HU, Ytting H, Ben Belkacem K, Chazouilleres O, Almer S; International PSC Study Group, Bergquist A. Clin Gastroenterol Hepatol. 2020 Feb 15:S1542-3565(20)30182-8. doi: 10.1016/j.cgh.2020.02.014.
  • Extrahepatic portal vein obstruction (EHPVO) in cirrhosis. Abergel A, Gasperment M, Nery FG, Buchard B, Lebreton A, Hordonneau C, Duron C, Valla D, Sophie H, Ledain-Rautou E, Hernandez-Gea V, Dutheil D, Plessier A, Bureau C, Francoz C. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):497-502. doi: 10.1016/j.clinre.2020.03.014.
  • Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(). Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, Aithal GP, Allison M, Yki-Järvinen H, Vacca M, Dufour JF, Invernizzi P, Prati D, Ekstedt M, Kechagias S, Francque S, Petta S, Bugianesi E, Clement K, Ratziu V, Schattenberg JM, Valenti L, Day CP, Cordell HJ, Daly AK; EPoS Consortium Investigators. J Hepatol. 2020 Sep;73(3):505-515. doi: 10.1016/j.jhep.2020.04.003.
  • Genotype correlates with the natural history of severe bile salt export pump deficiency. van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Sokal E, Grammatikopoulos T, Kadaristiana A, Jacquemin E, Spraul A, Lipiński P, Czubkowski P, Rock N, Shagrani M, Broering D, Algoufi T, Mazhar N, Nicastro E, Kelly D, Nebbia G, Arnell H, Fischler BR, Hulscher JBF, Serranti D, Arikan C, Polat E, Debray D, Lacaille F, Goncalves C, Hierro L, Muñoz Bartolo G, Mozer-Glassberg Y, Azaz A, Brecelj J, Dezsőfi A, Calvo PL, Grabhorn E, Sturm E, van der Woerd WJ, Kamath BM, Wang JS, Li L, Durmaz Ö, Onal Z, Bunt TM, Hansen B, Verkade HJ. J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105-7. doi: 10.1016/j.jhep.2020.02.007.
  • High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, Taubert R, Jaeckel E, Manns MP, Papp M, Sipeki N, Stickel F, Efe C, Ozaslan E, Purnak T, Nevens F, Kessener DJN, Kahraman A, Wedemeyer H, Hartl J, Schramm C, Lohse AW, Heneghan MA, Drenth JPH. Liver Int. 2020 May 14. doi: 10.1111/liv.14513.
  • Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis. Ronca V, Mancuso C, Milani C, Carbone M, Oo YH, Invernizzi P. J Leukoc Biol. 2020 Aug;108(2):659-671. doi: 10.1002/JLB.5MR0320-200R.
  • Ischemic cholangiopathy: An update. Goria O, Archambeaud I, Lemaitre C, Dutheil D, Plessier A, Rautou PE, Hernandez-Gea V, Valla D. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):486-490. doi: 10.1016/j.clinre.2020.03.018.
  • J. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores G. Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
  • Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of alpha-1 antitrypsin (Pi*MZ vs Pi*ZZ genotype) and Non-carriers. Schneider CV*, Hamesch K*, Gross A, Mandorfer M, Moeller LS, Pereira V, Pons M, Kuca P, Reichert MC, Benini F, Burbaum B, Voss J, Gutberlet M, Woditsch V, Lindhauer C, Fromme M, Kümpers J, Bewersdorf L, Schäfer B, Eslam M, Bals R, Janciauskiene S, Carvão J, Neureiter D, Zhou B, Wöran K, Bantel H, Geier A, Dirrichs T, Stickel F, Teumer A, Verbeek J, Nevens F, Govaere O, Krawczyk M, Roskams T, Haybaeck J, Lurje G, Chorostowska-Wynimko J, Genesca J, Reiberger T, Zoller H, Lammert F, Krag A, George J, Anstee QM, Trauner M, Datz C, Gaisa NT, Denk H, Trautwein C, Aigner E, Strnad P 2020 May 3. Pii: S0016-5085(20)30577-1 * equal contribution. Gastroenterology (2020), doi: https://doi.org/10.1053/j.gastro.2020.04.058.
  • Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension. Elkrief L, Lazareth M, Chevret S, Paradis V, Magaz M, Blaise L, Rubbia-Brandt L, Moga L, Durand F, Payancé A, Plessier A, Chaffaut C, Valla D, Malphettes M, Diaz A, Nault JC, Nahon P, Audureau E, Ratziu V, Castera L, Garcia Pagan JC, Ganne-Carrie N, Rautou PE; ANRS CO12 CirVir group. Hepatology. 2020 Dec 21. doi: 10.1002/hep.31688.
  • Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. Corpechot C, Chazouillères O, Belnou P, Montano-Loza AJ, Mason A, Ebadi M, Eurich D, Chopra S, Jacob D, Schramm C, Sterneck M, Bruns T, Reuken P, Rauchfuss F, Roccarina D, Thorburn D, Gerussi A, Trivedi P, Hirschfield G, McDowell P, Nevens F, Boillot O, Bosch A, Giostra E, Conti F, Poupon R, Parés A, Reig A, Donato MF, Malinverno F, Floreani A, Russo FP, Cazzagon N, Verhelst X, Goet J, Harms M, van Buuren H, Hansen B, Carrat F, Dumortier J; Global PBC Study Group. J Hepatol. 2020 Sep;73(3):559-565. doi: 10.1016/j.jhep.2020.03.043.
  • Management of anticoagulation in adult patients with chronic parenchymal or vascular liver disease: Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver. Ollivier-Hourmand I, Nguyen N, De Gottardi A, Valla D, Hillaire S, Dutheil D, Bureau C, Hernandez-Gea V, De Raucourt E, Plessier A. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):438-446. doi: 10.1016/j.clinre.2020.03.006.
  • Management of patients with autoimmune liver disease during COVID-19 pandemic. Lleo A, Invernizzi P, Lohse AW, Aghemo A, Carbone M. J Hepatol. 2020 Aug;73(2):453-455. doi: 10.1016/j.jhep.2020.04.002. Epub 2020 Apr 10.
  • Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Gerussi A, Bernasconi DP, O'Donnell SE, Lammers WJ, Van Buuren H, Hirschfield G, Janssen H, Corpechot C, Reig A, Pares A, Battezzati PM, Zuin MG, Cazzagon N, Floreani A, Nevens F, Gatselis N, Dalekos G, Mayo MJ, Thorburn D, Bruns T, Mason AL, Verhelst X, Kowdley K, van der Meer A, Niro GA, Beretta-Piccoli BT, Marzioni M, Belli LS, Marra F, Valsecchi MG, Lindor KD, Invernizzi P, Hansen BE, Carbone M. Clin Gastroenterol Hepatol. 2020 Aug 7;S1542-3565(20)31083-1. doi: 10.1016/j.cgh.2020.08.006.
  • Open challenges in the management of autoimmune hepatitis. Gerussi A, Halliday N, Carbone M, Invernizzi P, Thorburn D. Minerva Gastroenterol Dietol. 2020 Dec 3. doi: 10.23736/S1121-421X.20.02805-6.
  • Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction. Elkrief L, Houssel-Debry P, Ackermann O, Franchi-Abella S, Branchereau S, Valla D, Hillaire S, Dutheil D, Plessier A, Hernandez-Gea V, Bureau C. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):491-496. doi: 10.1016/j.clinre.2020.03.016.
  • Porto-sinusoidal vascular disease. Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver. Giudicelli H, Rautou PE, Paradis V, Bedossa P, Goria O, Lambert V, Hernandez-Gea V, Dutheil D, Plessier A, Bureau C, Valla D. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):447-451. doi: 10.1016/j.clinre.2020.03.005.
  • Pregnancy and vascular liver diseases. Payancé A, Ceccaldi PF, De Raucourt E, Valla D, Hillaire S, Dutheil D, Hernandez-Gea V, Bureau C, Plessier A. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):433-437. doi: 10.1016/j.clinre.2020.03.007.
  • Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, Taubert R, Jaeckel E, Manns MP, Papp M, Sipeki N, Stickel F, Efe C, Ozaslan E, Purnak T, Nevens F, Kessener DJN, Kahraman A, Wedemeyer H, Hartl J, Schramm C, Lohse AW, Drenth JPH, Heneghan MA. Clin Gastroenterol Hepatol. 2020 Jun;18(7):1609-1617.e4. doi: 10.1016/j.cgh.2019.11.013. Epub 2019 Nov 9.
  • Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Trebicka J, Gu W, Ibáñez-Samaniego L, Hernández-Gea V, Pitarch C, Garcia E, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, Silva-Junior G, Martinez J, Genescà J, Bureau C, Llop E, Laleman W, Palazon JM, Castellote J, Rodrigues S, Gluud L, Ferreira CN, Barcelo R, Cañete N, Rodríguez M, Ferlitsch A, Mundi JL, Gronbaek H, Hernández-Guerra M, Sassatelli R, Dell'Era A, Senzolo M, Abraldes JG, Romero-Gómez M, Zipprich A, Casas M, Masnou H, Primignani M, Weiss E, Catalina MV, Erasmus HP, Uschner FE, Schulz M, Brol MJ, Praktiknjo M, Chang J, Krag A, Nevens F, Calleja JL, Robic MA, Conejo I, Albillos A, Rudler M, Alvarado E, Guardascione MA, Tantau M, Bosch J, Torres F, Pavesi M, Garcia-Pagán JC, Jansen C, Bañares R; International Variceal Bleeding Observational Study Group and Baveno Cooperation. J Hepatol. 2020 Nov;73(5):1082-1091. doi: 10.1016/j.jhep.2020.04.024.
  • Recent (non-cirrhotic) extrahepatic portal vein obstruction. Heurgué A, Habes D, Brugel M, Franchi-Abella S, Condat B, Valla D, Hillaire S, Debray D, Hernandez-Gea V, Dutheil D, Plessier A, Bureau C, Payancé A. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):460-465. doi: 10.1016/j.clinre.2020.03.003.
  • Risk factors for vascular liver diseases: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver. Soret J, Debray D, Fontbrune FS, Kiladjian JJ, Saadoun D, Latour RP, Valla D, Hernandez-Gea V, Hillaire S, Dutheil D, Plessier A, Bureau C, De Raucourt E. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):410-419. doi: 10.1016/j.clinre.2020.03.010.
  • Second-line and Third-line therapy for Autoimmune Hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. Lohse AW, Sebode M, Jørgensen MH, Ytting H, Karlsen TH, Kelly D, Manns MP, Vesterhus M; European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and of the International Autoimmune Hepatitis Group (IAIHG). J Hepatol. 2020 Jul 21:S0168-8278(20)30470-0. doi: 10.1016/j.jhep.2020.07.023. Online ahead of print.
  • Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. Murillo Perez CF, Gulamhusein A, Carbone M, Trivedi PJ, van der Meer AJ, Corpechot C, Battezzati PM, Lammers WJ, Cazzagon N, Floreani A, Parés A, Nevens F, Lleo A, Mayo MJ, Kowdley KV, Ponsioen CY, Dalekos GN, Gatselis NK, Thorburn D, Mason AL, Janssen H, Verhelst X, Bruns T, Lindor KD, Chazouillères O, Invernizzi P, Hansen BE, Hirschfield GM; GLOBAL PBC Study Group. Eur J Gastroenterol Hepatol. 2020 Dec 14. doi: 10.1097/MEG.0000000000002029.
  • Sinusoidal obstruction syndrome. de Lédinghen V, Villate A, Robin M, Decraecker M, Valla D, Hillaire S, Hernandez-Gea V, Dutheil D, Bureau C, Plessier A. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):480-485. doi: 10.1016/j.clinre.2020.03.019
  • Social and medical support initiatives in vascular liver diseases in France, from child to adult. Plessier A, Gasperment M, Debray D, Brault C, Ollivier-Hourmand I, Dutheil D, Leclercq A, Devictor J, Hernández-Gea V, Le Beux E, Goria O. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):466-470. doi: 10.1016/j.clinre.2020.03.002.
  • Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Hepatology. 2020 Nov 20. doi: 10.1002/hep.31646.

2019

  • Clinical management of autoimmune hepatitis. Pape S, Schramm C, Gevers TJ. United European Gastroenterol J. 2019 Nov;7(9):1156-1163. doi: 10.1177/2050640619872408. Epub 2019 Aug 25. Review.
  • Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. Hernández-Gea V, De Gottardi A, Leebeek FWG, Rautou PE, Salem R, Garcia-Pagan JC. J Hepatol. 2019 Jul;71(1):175-199. doi: 10.1016/j.jhep.2019.02.015. Epub 2019 Feb 26. Review.
  • Depression in patients with autoimmune hepatitis: the need for detailed psychiatric assessment. Janik MK, Wunsch E, Moskwa M, Raszeja-Wyszomirska J, Krawczyk M, Milkiewicz P. Pol Arch Intern Med. 2019 Sep 30;129(9):645-647. doi: 10.20452/pamw.14898. Epub 2019 Jul 12.
  • Efficacy of rituximab in difficult-to-manage Autoimmune Hepatitis: Results from the International Autoimmune Hepatitis Group. Than NN, Hodson J, Schmidt-Martin D, Taubert R, Wawman RE, Botter M, Gautam N, Bock K, Jones R, Appanna GD, Godkin A, Montano-Loza AJ, Lammert F, Schramm C, Manns MP, Swain M, Burak KW, Adams DH, Hirschfield GM, Oo YH. JHEP Reports. Nov 2019. Volume 1, Issue 6, Pages 437-445. Doi: 10.1016/j.jhepr.2019.10.005.
  • Liver Fibrosis and Metabolic Alterations in Adults with Alpha-1 Antitrypsin Deficiency Caused by the Pi*ZZ Mutation; Hamesch K, Mandorfer M, Pereira VM, Moeller LS, Pons M, Dolman GE, Reichert MC, Heimes CV, Woditsch V, Voss J, Lindhauer C, Fromme M, Spivak I, Guldiken N, Zhou B, Arslanow A, Schaefer B, Zoller H, Aigner E, Reiberger T, Wetzel M, Siegmund B, Simões C, Gaspar R, Maia L, Costa D, Bento-Miranda M, van Helden J, Yagmur E, Bzdok D, Stolk J, Gleiber W, Knipel V, Windisch W, Mahadeva R, Bals R, Koczulla R, Barrecheguren M, Miravitlles M, Janciauskiene S, Stickel F, Lammert F, Liberal R, Genesca J, Griffiths WJ, Trauner M, Krag A, Trautwein C, Strnad P. Gastroenterology 2019 Sep;157(3):705-719.e18
  • Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER. Bernts LHP, Jones DEJ, Kaatee MM, Lohse AW, Schramm C, Sturm E, Drenth JPH. ORPHANET JOURNAL OF RARE DISEASES. JUL 8, 2019. Doi: 10.1186/s13023-019-1152-z.
  • The challenges of primary biliary cholangitis: What is new and what needs to be done. Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. J Autoimmun. 2019 Dec;105:102328. doi: 10.1016/j.jaut.2019.102328. Epub 2019 Sep 20. Review.

2018

  • Access to care in rare liver diseases: New challenges and new opportunities: Jones, D. E. J., Sturm, E. & Lohse, J Hepatol. 2018 Mar;68(3):577-585. doi: 10.1016/j.jhep.2017.11.004. Epub 2017 Nov 4.
  • Drug holiday in patients with polycystic liver disease treated with somatostatin analogues. van Aerts RMM, Kolkman M, Kievit W, Gevers TJG, Nevens F, Drenth JPH. Therap Adv Gastroenterol. 2018 Oct 3;11:1756284818804784. doi: 10.1177/1756284818804784.
  • Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, McQuillin A, Reichert MC, Krawczyk M, Casper M, Lammert F, Braun F, von Schönfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Kiefer F, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay A, Schlattjan M, Sosnowsky K, Sarrazin C, von Felden J, Geier A, Deltenre P, Sipos B, Schafmayer C, Nothnagel M, Aigner E, Datz C, Stickel F, Morgan MY, Hampe J, Berg T, Trautwein C. Gut. 2018 Aug 1. pii: gutjnl-2018-316228. doi: 10.1136/gutjnl-2018-316228.


Scientific Publications

2021

  • ABCB4-alteration screening in adult-onset cholestasis. Carbone M, Cardinale V. Dig Liver Dis. 2021 Jan 15:S1590-8658(21)00004-9. doi: 10.1016/j.dld.2020.12.121.
  • Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis. Kiladjian JJ, Debureaux PE, Plessier A, Soret-Dulphy J, Valla D, Cassinat B, Rautou PE. J Hepatol. 2021 Jan;74(1):251-252. doi: 10.1016/j.jhep.2020.07.043.
  • CK-18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission. Derben FC, Engel B, Zachou K, Hartl J, Hartleben B, Bantel H, Schramm C, Dalekos GN, Manns MP, Jaeckel E, Taubert R. Liver Int. 2021 Jan;41(1):123-127. doi: 10.1111/liv.14699.
  • Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Med Clin (Barc). 2021 Jan 15:S0025-7753(20)30769-7. doi: 10.1016/j.medcli.2020.09.022.
  • Failure to control variceal bleeding: definition matters. Baiges A, Bureau C, García-Pagán JC. J Hepatol. 2021 Jan 19:S0168-8278(21)00021-0. doi: 10.1016/j.jhep.2021.01.012.
  • Reply to: "A spotlight on natural killer cells in primary biliary cholangitis". Carbone M, Ronca V, Invernizzi P. J Hepatol. 2021 Jan;74(1):255-256. doi: 10.1016/j.jhep.2020.09.020.
  • Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis". Magaz M, Alvarez-Larrán A, Colomer D, López M, Turon F, Cervantes F, Virginia-Hernández-Gea, García-Pagán JC. J Hepatol. 2021 Jan;74(1):252-254. doi: 10.1016/j.jhep.2020.09.009.
  • Response to: The Pi*MZ Allele in Alpha-1 Antitrypsin Increases Liver-Related Outcomes in a Population-Based Study. Schneider CV, Hamesch K, Strnad P. Gastroenterology. 2021 Jan 5:S0016-5085(21)00014-7. doi: 10.1053/j.gastro.2021.01.002.
  • Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients. Rahim MN, Theocharidou E, Yen Lau KG, Ahmed R, Marattukalam F, Long L, Cannon MD, Heneghan MA. J Hepatol. 2021 Jan 15:S0168-8278(21)00005-2. doi: 10.1016/j.jhep.2020.12.022.
  • SARS-CoV-2 infection in patients with autoimmune hepatitis. Marjot T, Buescher G, Sebode M, Barnes E, Barritt AS 4th, Armstrong MJ, Baldelli L, Kennedy J, Mercer C, Ozga AK, Casar C, Schramm C; Contributing Members and Collaborators of ERN RARE-LIVER / COVID-Hep / SECURE-Cirrhosis, Moon AM, Webb GJ, Lohse AW. J Hepatol. 2021 Jan 26:S0168-8278(21)00033-7. doi: 10.1016/j.jhep.2021.01.021.
  • Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. Galaski J, Weiler-Normann C, Schakat M, Zachou K, Muratori P, Lampalzer S, Haag F, Schramm C, Lenzi M, Dalekos GN, Lohse AW. J Hepatol. 2021 Feb;74(2):312-320. doi: 10.1016/j.jhep.2020.07.032.

2020

  • A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis. Hammoutene A, Biquard L, Lasselin J, Kheloufi M, Tanguy M, Vion AC, Mérian J, Colnot N, Loyer X, Tedgui A, Codogno P, Lotersztajn S, Paradis V, Boulanger CM, Rautou PE. J Hepatol. 2020 Mar;72(3):528-538. doi: 10.1016/j.jhep.2019.10.028. Epub 2019 Nov 11.
  • A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis. Liwinski T, Casar C, Ruehlemann MC, Bang C, Sebode M, Hohenester S, Denk G, Lieb W, Lohse AW, Franke A, Schramm C. Aliment Pharmacol Ther. 2020 Jun;51(12):1417-1428. doi: 10.1111/apt.15754.
  • Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. Wang L, Guo X, Xu X, De Stefano V, Plessier A, Noronha Ferreira C, Qi X. Adv Ther. 2020 Nov 5. doi: 10.1007/s12325-020-01550-4.
  • Autoantibodies to intracellular "rods and rings" structures in two patients with autoimmune hepatitis treated with azathioprine. Galaski J, Koop AC, Lütgehetmann M, Lohse AW, Weiler-Normann C. Autoimmunity. 2020 Sep;53(6):362-365. doi: 10.1080/08916934.2020.1793135.
  • Autoimmune Hepatitis: Tolerogenic Immunological State During Pregnancy and Immune Escape in Post-partum. Bozward AG, Wootton GE, Podstawka O, Oo YH. Front Immunol. 2020 Sep 24;11:591380. doi: 10.3389/fimmu.2020.591380.
  • Case report: progressive familial intrahepatic cholestasis type 3 with compound heterozygous ABCB4 variants diagnosed 15 years after liver transplantation. Goubran M, Aderibigbe A, Jacquemin E, Guettier C, Girgis S, Bain V, Mason AL. BMC Med Genet. 2020 Nov 30;21(1):238. doi: 10.1186/s12881-020-01173-0.
  • Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients. Gerussi A, Rigamonti C, Elia C, Cazzagon N, Floreani A, Pozzi R, Pozzoni P, Claar E, Pasulo L, Fagiuoli S, Cristoferi L, Carbone M, Invernizzi P. Hepatol Commun. 2020 Jun 9;4(9):1257-62. doi: 10.1002/hep4.1557.
  • Cost of illness of Primary Biliary Cholangitis - a population-based study. Gerussi A, Restelli U, Croce D, Bonfanti M, Invernizzi P, Carbone M. Dig Liver Dis. 2020 Aug 21:S1590-8658(20)30387-X. doi: 10.1016/j.dld.2020.07.029.
  • DCLK1, a putative novel stem cell marker in human cholangiocarcinoma. Nevi L, Di Matteo S, Carpino G, Zizzari I, Safarikia S, Ambrosino V, Costantini D, Overi D, Giancotti A, Monti M, Bosco D, De Peppo V, Oddi A, De Rose AM, Melandro F, Bragazzi MC, Faccioli J, Massironi S, Grazi GL, Panici PB, Berloco PB, Giuliante F, Cardinale V, Invernizzi P, Caretti G, Gaudio E, Alvaro D. Hepatology. 2020 Sep 25. doi: 10.1002/hep.31571.
  • Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy. Montano-Loza AJ, Corpechot C. Clin Gastroenterol Hepatol. 2020 Jul 3:S1542-3565(20)30926-5. doi: 10.1016/j.cgh.2020.06.062.
  • Direct oral anticoagulants and advanced liver disease: A systematic review and meta-analysis. Menichelli D, Ronca V, Di Rocco A, Pignatelli P, Marco Podda G; CAR. Eur J Clin Invest. 2020 Sep 7:e13397. doi: 10.1111/eci.13397.
  • Editorial: gut microbiota profile in patients with autoimmune hepatitis-a clue for adjunctive probiotic therapy? Authors' reply. Liwinski T, Schramm C. Aliment Pharmacol Ther. 2020 Jul;52(2):394-395. doi: 10.1111/apt.15819.
  • Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series. Bernts LHP, Dekker SEI, Soonawala D, Brüggemann RJM, Wertheim HFL, de Fijter JW, Drenth JPH, Lantinga MA. J Antimicrob Chemother. 2020 May 21:dkaa186. doi: 10.1093/jac/dkaa186.
  • Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy. Massironi S, Viganò C, Dioscoridi L, Filippi E, Pagliarulo M, Manfredi G, Conti CB, Signorelli C, Redaelli AE, Bonato G, Iiritano E, Frego R, Zucchini N, Ungari M, Pedaci M, Bono F, Di Bella C, Buscarini E, Mutignani M, Penagini R, Dinelli ME, Invernizzi P. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2375-2377. doi: 10.1016/j.cgh.2020.05.045.
  • Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm. Poisson J, Tanguy M, Davy H, Camara F, El Mdawar MB, Kheloufi M, Dagher T, Devue C, Lasselin J, Plessier A, Merchant S, Blanc-Brude O, Souyri M, Mougenot N, Dingli F, Loew D, Hatem SN, James C, Villeval JL, Boulanger CM, Rautou PE. J Clin Invest. 2020 May 1;130(5):2630-2643. doi: 10.1172/JCI124566.
  • Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view. Thietart S, Rautou PE. J Hepatol. 2020 Dec;73(6):1507-1525. doi: 10.1016/j.jhep.2020.07.014.
  • Glycerol Phenylbutyrate Therapy in Progressive Familial Intrahepatic Cholestasis Type 2. Almes M, Jobert A, Lapalus M, Mareux E, Gonzales E, Jacquemin E. J Pediatr Gastroenterol Nutr. 2020 Jun;70(6):e139-e140. doi: 10.1097/MPG.0000000000002713.
  • Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium. Verhelst X, Somers N, Geerts A, Degroote H, Van Vlierberghe H. J Hepatol. 2020 Sep 10:S0168-8278(20)33605-9. doi: 10.1016/j.jhep.2020.08.035.
  • Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium. Verhelst X, Somers N, Geerts A, Degroote H, Van Vlierberghe H. J Hepatol. 2021 Jan;74(1):240-241. doi: 10.1016/j.jhep.2020.08.035.
  • Hereditary hemorrhagic telangiectasia and liver involvement: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver. Silvain C, Thévenot T, Colle I, Vilgrain V, Dupuis-Girod S, Buscarini E, Valla D, Hillaire S, Dutheil D, Sitbon O, Bureau C, Plessier A. Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):426-432. doi: 10.1016/j.clinre.2020.03.008.
  • High rates of 30-day mortality in patients with cirrhosis and COVID-19. Iavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, Perricone G, Massironi S, Spinetti A, Buscarini E, Viganò M, Carriero C, Fagiuoli S, Aghemo A, Belli LS, Lucà M, Pedaci M, Rimondi A, Rumi MG, Invernizzi P, Bonfanti P, Lampertico P. J Hepatol. 2020 Nov;73(5):1063-1071. doi: 10.1016/j.jhep.2020.06.001.
  • Identifying Racial Disparities in Primary Biliary Cholangitis Patients: A Step Toward Achieving Equitable Outcomes Among All. Palermo A, Gerussi A, Mulinacci G, Invernizzi P, Carbone M. Dig Dis Sci. 2020 Aug 13. doi: 10.1007/s10620-020-06528-4.
  • Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). Panzuto F, Maccauro M, Campana D, Faggiano A, Massironi S, Pusceddu S, Spada F, Ferone D, Modica R, Grana CM, Ferolla P, Rinzivillo M, Badalamenti G, Zatelli MC, Gelsomino F, De Carlo E, Bartolomei M, Brizzi MP, Cingarlini S, Versari A, Fanciulli G, Arvat E, Merola E, Cives M, Tafuto S, Baldari S, Falconi M. J Endocrinol Invest. 2020 Aug 16:1-6. doi: 10.1007/s40618-020-01393-4.
  • Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate. Smets L, Verbeek J, Korf H, van der Merwe S, Nevens F. Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
  • Long-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival? Creutzfeldt AM, Piecha F, Schattenberg JM, Schramm C, Lohse AW. J Hepatol. 2020 Nov;73(5):1285-1287. doi: 10.1016/j.jhep.2020.07.027. Epub 2020 Aug 27.
  • Long-term survival after liver transplantation for autoimmune hepatitis - results from the European Liver Transplant Registry. Heinemann M, Adam R, Berenguer M, Mirza D, Malek-Hosseini SA, O'Grady JG, Lodge P, Pratschke J, Boudjema K, Paul A, Zieniewicz K, Fronek J, Weiss KH, Karam V, Duvoux C, Lohse A, Schramm C. Liver Transpl. 2020 Feb 29. doi: 10.1002/lt.25739.
  • Management of cholangiocarcinoma in the third millennium: time to be guided! Carbone M, Baiocchi L. Dig Liver Dis. 2020 Dec;52(12):1428-1429. doi: 10.1016/j.dld.2020.11.003.
  • Metamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury. Sebode M, Reike-Kunze M, Weidemann S, Zenouzi R, Hartl J, Peiseler M, Liwinski T, Schulz L, Weiler-Normann C, Sterneck M, Lohse AW, Schramm C. Br J Clin Pharmacol. 2020 Feb 20. doi: 10.1111/bcp.14254.
  • Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Debureaux PE, Cassinat B, Soret-Dulphy J, Mora B, Verger E, Maslah N, Plessier A, Rautou PE, Ollivier-Hourman I, De Ledinghen V, Goria O, Bureau C, Siracusa C, Valla D, Giraudier S, Passamonti F, Kiladjian JJ. Blood Adv. 2020 Aug 11;4(15):3708-3715. doi: 10.1182/bloodadvances.2020002414.
  • Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies.Gerussi A, D'Amato D, Cristoferi L, O'Donnell SE, Carbone M, Invernizzi P. Ann Hepatol. 2020 Jan - Feb;19(1):5-16. doi: 10.1016/j.aohep.2019.09.009. Epub 2019 Oct 31. Review.
  • New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease. Barten, T. R., Bernts, L. H., Drenth, J. P., & Gevers, T. J. Expert Opinion on Therapeutic Targets (2020), 24(6), 589-599. DOI: 10.1080/14728222.2020.1751818
  • New Therapeutic Targets in Autoimmune Cholangiopathies. Gerussi A, Lucà M, Cristoferi L, Ronca V, Mancuso C, Milani C, D'Amato D, O'Donnell SE, Carbone M, Invernizzi P. Front Med (Lausanne). 2020 Apr 7;7:117. doi: 10.3389/fmed.2020.00117.
  • Non-Invasive Assessment and Management of Liver Involvement in Adults With Alpha-1 Antitrypsin Deficiency. Hamesch K, Strnad P. Chronic Obstr Pulm Dis. 2020 Jul;7(3):260-271. doi: 10.15326/jcopdf.7.3.2019.0161.
  • Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies. Höfer A, Jonigk D, Hartleben B, Verboom M, Hallensleben M, Manns MP, Jaeckel E, Taubert R. Sci Rep. 2020 Aug 28;10(1):14242. doi: 10.1038/s41598-020-70938-7.
  • Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis. Moga L, Laroyenne A, Larrue H, Bureau C, Rautou PE. J Hepatol. 2020 Oct 23:S0168-8278(20)33691-6. doi: 10.1016/j.jhep.2020.10.011.
  • Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. Sebode M, Kloppenburg A, Aigner A, Lohse AW, Schramm C, Linder R. Z Gastroenterol. 2020 May;58(5):431-438. doi: 10.1055/a-1135-9306.
  • Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. Abenavoli L, Procopio AC, Fagoonee S, Pellicano R, Carbone M, Luzza F, Invernizzi P. Diseases. 2020 Jun 10;8(2):20. doi: 10.3390/diseases8020020.
  • Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. Alvaro D, Carpino G, Craxi A, Floreani A, Moschetta A, Invernizzi P. Liver Int. 2020 Nov;40(11):2590-2601. doi: 10.1111/liv.14627.
  • Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets. Carbone M, Milani C, Gerussi A, Ronca V, Cristoferi L, Invernizzi P. J Hepatol. 2020 Oct;73(4):965-966. doi: 10.1016/j.jhep.2020.05.041.
  • Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy. Carbone M, Kodra Y, Rocchetti A, Manno V, Minelli G, Gerussi A, Ronca V, Malinverno F, Cristoferi L, Floreani A, Invernizzi P, Conti S, Taruscio D. Int J Environ Res Public Health. 2020 Apr 29;17(9):3095. doi: 10.3390/ijerph17093095.
  • Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis". Lohse AW, Sebode M, Vesterhus M. J Hepatol. 2020 Dec 9:S0168-8278(20)33818-6. doi: 10.1016/j.jhep.2020.11.031.
  • Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?": pTIPS for variceal bleeding in ACLF patients: when and why? Trebicka J, Gu W, Garcia-Pagán JC, Bosch J, Bañares R. J Hepatol. 2020 Oct;73(4):977-979. doi: 10.1016/j.jhep.2020.05.037.
  • Reply to: "Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications". Ferrusquía-Acosta J, Turco L, Hernández-Gea V. J Hepatol. 2020 Dec 29:S0168-8278(20)33837-X. doi: 10.1016/j.jhep.2020.12.001.
  • Risk stratification in primary sclerosing cholangitis. Mulinacci G, Cristoferi L, Palermo A, Lucà M, Gerussi A, Invernizzi P, Carbone M. Minerva Gastroenterol Dietol. 2020 Dec 10. doi: 10.23736/S1121-421X.20.02821-4.
  • Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma. Souhami A, Sartoris R, Rautou PE, Cauchy F, Bouattour M, Durand F, Gianelli V, Gigante E, Castera L, Valla D, Soubrane O, Vilgrain V, Ronot M. JHEP Rep. 2020 Jul 17;2(5):100147. doi: 10.1016/j.jhepr.2020.100147.
  • Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. Bossen L, Rebora P, Bernuzzi F, Jepsen P, Gerussi A, Andreone P, Galli A, Terziroli B, Alvaro D, Labbadia G, Aloise C, Baiocchi L, Giannini E, Abenavoli L, Toniutto P, Marra F, Marzioni M, Niro G, Floreani A, Møller HJ, Valsecchi MG, Carbone M, Grønbaek H, Invernizzi P. Liver Int. 2020 Jun;40(6):1408-1414. doi: 10.1111/liv.14466.
  • Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience. Corpechot C, Rousseau A, Chazouillères O. J Hepatol. 2020 Jun;72(6):1210-1211. doi: 10.1016/j.jhep.2019.12.027.
  • Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study. Nery F, Carneiro P, Correia S, Macedo C, Gandara J, Lopes V, Valadares D, Ferreira S, Oliveira J, Teixeira Gomes M, Miranda HP, Rautou PE, Valla D. Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000001982.
  • The future of autoimmune liver diseases - Understanding pathogenesis and improving morbidity and mortality. Engel B, Taubert R, Jaeckel E, Manns MP. Liver Int. 2020 Feb;40 Suppl 1:149-153. doi: 10.1111/liv.14378. Review.
  • The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations. Terry LV, Oo YH. Front Immunol. 2020 Sep 23;11:565518. doi: 10.3389/fimmu.2020.565518.
  • Therapeutic plasma exchange in acute on chronic liver failure. Stahl K, Busch M, Fuge J, Schneider A, Manns MP, Seeliger B, Schmidt JJ, Wiesner O, Schmidt BMW, Taubert R, Vondran FWR, Hoeper MM, David S. J Clin Apher. 2020 Aug;35(4):316-327. doi: 10.1002/jca.21799.
  • Up to 50% of portal vein thrombosis remains undiagnosed until liver transplantation. Bert J, Geerts A, Vanlander A, Abreu de Carvalho L, Degroote H, Berrevoet F, Rogiers X, van Vlierberghe H, Verhelst X. Clin Transplant. 2020 Dec;34(12):e14107. doi: 10.1111/ctr.14107.
  • Ursodeoxycholic acid therapy throughout pregnancy in women affected with chronic cholestasis of childhood: No evidence for teratogenicity. Lykavieris P, Bernard O, Jacquemin E. Clin Res Hepatol Gastroenterol. 2020 Jun 18:S2210-7401(20)30165-0. doi: 10.1016/j.clinre.2020.05.020.
  • Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Pomej K, Scheiner B, Park D, Bauer D, Balcar L, Meischl T, Mandorfer M, Reiberger T, Müller C, Trauner M, Pinter M. Cancers (Basel). 2020 Oct 13;12(10):2961. doi: 10.3390/cancers12102961.
  • Why and when to diagnose Behcet's disease in patients with Budd Chiari Syndrome? Desbois AC, Plessier A. Clin Res Hepatol Gastroenterol. 2020 Jan 6. pii: S2210-7401(19)30264-5. doi: 10.1016/j.clinre.2019.12.003.

2019

  • Assessment of liver phenotype in adults with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype). Kümpers J, Fromme M, Schneider CV, Trautwein C, Denk H, Hamesch K, Strnad P. J Hepatol. 2019 Dec;71(6):1272-1274. doi: 10.1016/j.jhep.2019.08.011. Epub 2019 Oct 5.
  • Better end points needed in primary sclerosing cholangitis trials. Gerussi A, Invernizzi P. Nat Rev Gastroenterol Hepatol. 2019 Jan 17. doi: 10.1038/s41575-019-0110-5. [Epub ahead of print] No abstract available.
  • Congenital Portosystemic Shunts: Current Diagnosis and Management. McLin VA, Franchi-Abella S, Debray D, Guérin F, Beghetti M, Savale L, Wildhaber BE, Gonzales E; Members of the International Registry of Congenital Porto-Systemic Shunts. J Pediatr Gastroenterol Nutr. 2019 Jan 4. doi: 10.1097/MPG.0000000000002263. [Epub ahead of print]
  • DEFI-ALFA: The French key to the alpha1 mystery? Fromme M, Oliverius M, Strnad P. Liver Int. 2019 Jun;39(6):1019-1021. doi: 10.1111/liv.14064.
  • Effects of Age and Sex of on Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HL, Hansen BE; Global PBC Study Group. Clin Gastroenterol Hepatol. 2019 Jan 4. pii: S1542-3565(19)30001-1. doi: 10.1016/j.cgh.2018.12.028. [Epub ahead of print]
  • Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Montano-Loza AJ, Hansen BE, Corpechot C, Roccarina D, Thorburn D, Trivedi P, Hirschfield G, McDowell P, Poupon R, Dumortier J, Bosch A, Giostria E, Conti F, Parés A, Reig A, Floreani A, Russo FP, Goet JC, Harms MH, van Buuren H, Van den Ende N, Nevens F, Verhelst X, Donato MF, Malinverno F, Ebadi M, Mason AL; Global PBC Study Group. Gastroenterology. 2019 Jan;156(1):96-107.e1. doi:10.1053/j.gastro.2018.10.001. Epub 2018 Oct 6. PubMed PMID: 30296431.
  • Inflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis. Sebode M, Wigger J, Filpe P, Fischer L, Weidemann S, Krech T, Weiler-Normann C, Peiseler M, Hartl J, Tolosa E, Herkel J, Schramm C, Lohse AW, Arrenberg P. Front Immunol. 2019 May 28;10:1065. doi: 10.3389/fimmu.2019.01065. eCollection 2019.
  • Mild Iron Overload as Seen in Individuals Homozygous for the Alpha-1 Antitrypsin Pi*Z Variant Does Not Promote Liver Fibrogenesis in HFE Knockout Mice; Cells 2019 Nov 9;8(11). Pii: E1415 Guldiken N*, Hamesch K*, Schuller SM, Aly M, Lindhauer C, Schneider CV, Fromme M, Trautwein C, Strnad P: * equal contribution
  • Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. Gerussi A, D'Amato D, Cristoferi L, O'Donnell SE, Carbone M, Invernizzi P. Ann Hepatol. 2020 Jan - Feb;19(1):5-16. doi: 10.1016/j.aohep.2019.09.009. Epub 2019 Oct 31. Review.
  • Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. Abdulkarim M, Zenouzi R, Sebode M, Schulz L, Quaas A, Lohse AW, Schramm C, Weiler-Normann C. Scand J Gastroenterol. 2019 Nov;54(11):1391-1396. doi: 10.1080/00365521.2019.1683226. Epub 2019 Nov 6.

2018

  • "I Miss My Liver." Nonmedical Sources in the History of Hepatocentrism. Orlandi R, Cianci N, Invernizzi P, Cesana G, Riva MA. Hepatol Commun. 2018 Aug 6;2(8):982-989. doi: 10.1002/hep4.1224. eCollection 2018 Aug
  • A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R. N Engl J Med. 2018 Jun 7;378(23):2171-2181. doi: 10.1056/NEJMoa1714519. PubMed PMID: 29874528.
  • Ageing-related expression of Twinfilin-1 regulates cholangiocyte biological response to injury.Maroni L, Pinto C, Giordano DM, Saccomanno S, Banales JM, Spallacci D, Albertini MC, Orlando F, Provinciali M, Milkiewicz M, Melum E, Ciriza IL, Milkiewicz P, Rychlicki C, Trozzi L, Scarpelli M, Benedetti A, Svegliati Baroni G, Marzioni M. Hepatology. 2018 Dec 18. doi: 10.1002/hep.30466. [Epub ahead of print]
  • Al-Dury S, Wahlström A, Wahlin S, Langedijk J, Elferink RO, Ståhlman M, Marschall HU. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep. 2018 Apr27;8(1):6658. doi: 10.1038/s41598-018-25214-0. PubMed PMID: 29704003; PubMed Central PMCID: PMC5923243.
  • Autoimmune hepatitis From current knowledge and clinical practice to future research agenda. Sebode, M., Hartl, J., Vergani, D., Lohse, A. W. & International Autoimmune Hepatitis Group (IAIHG) 01.2018 in : LIVER INT. 38, 1, S. 15-22
  • Bile Acids, the Microbiome, Immunity, and Liver Tumors Schramm, C. 30.08.2018 in : NEW ENGL J MED. 379, 9, S. 888-890
  • Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2-/- mice and human cholangiocarcinoma tumorigenesis. Kennedy L, Hargrove L, Demieville J, Karstens W, Jones H, DeMorrow S, Meng F, Invernizzi P, Bernuzzi F, Alpini G, Smith S, Akers A, Meadows V, Francis H. Hepatology. 2018 Mar 30. doi: 10.1002/hep.29898. [Epub ahead of print]
  • Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. Muratori P, Carbone M, Stangos G, Perini L, Lalanne C, Ronca V, Cazzagon N, Bianchi G, Lenzi M, Floreani A, Invernizzi P, Muratori L. Dig Liver Dis. 2018 Jul;50(7):698-702. doi: 10.1016/j.dld.2018.02.015. Epub 2018 Mar 2
  • Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. Carbone M, Harms MH, Lammers WJ, Marmon T, Pencek R, MacConell L, Shapiro D, Jones DE, Mells GF, Hansen BE. Hepatol Commun. 2018 Apr 19;2(6):683-692. doi: 10.1002/hep4.1180. eCollection 2018 Jun
  • Comparison of non-invasive assessment of liver fibrosis in patients with alpha1-antitrypsin deficiency using magnetic resonance elastography (MRE), acoustic radiation force impulse (ARFI) Quantification, and 2D-shear wave elastography (2D-SWE). Reiter R, Wetzel M, Hamesch K, Strnad P, Asbach P, Haas M, Siegmund B, Trautwein C, Hamm B, Klatt D, Braun J, Sack I, Tzschätzsch H. PLoS One. 2018 Apr 26;13(4):e0196486. doi: 10.1371/journal.pone.0196486. eCollection 2018.
  • Effects of liver transplantation on health-related quality of life in patients with primary biliary cholangitis. Krawczyk M, Koźma M, Szymańska A, Leszko K, Przedniczek M, Mucha K, Foroncewicz B, Pączek L, Moszczuk B, Milkiewicz P, Raszeja-Wyszomirska J. Clin Transplant. 2018 Dec;32(12):e13434. doi: 10.1111/ctr.13434. Epub 2018 Dec 6. PubMed PMID: 30362634.
  • European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019 Jan;70(1):172-193. doi: 10.1016/j.jhep.2018.06.024. Epub 2018 Aug 23. PubMed PMID: 30144956.
  • Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature. Carbone M, Bonato G, Invernizzi P. Hepatology. 2018 Apr;67(4):1210-1212. doi: 10.1002/hep.29625. Epub 2018 Feb 19. No abstract available
  • Fine-tuning of SIRT1 expression is essential to protect the liver from cholestatic liver disease. Blokker BA, Maijo M, Echeandia M, Galduroz M, Patterson AM, Ten A, Philo M, Schungel R, Gutierrez-de Juan V, Halilbasic E, Fuchs C, Le Gall G, Milkiewicz M, Milkiewicz P, Banales JM, Rushbrook SM, Mato JM, Trauner M, Müller M, Martínez-Chantar ML, Varela-Rey M, Beraza N. Hepatology. 2018 Sep 19. doi: 10.1002/hep.30275. [Epub ahead of print]
  • Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis Alberts, R. , de Vries, E. M. G. , Goode, E. C. , Jiang, X. , Sampaziotis, F. , Rombouts, K. , Böttcher, K. , Folseraas, T. , Weismüller, T. J. , Mason, A. L. , Wang, W. , Alexander, G. , Alvaro, D. , Bergquist, A. , Björkström, N. K. , Beuers, U. , Björnsson, E. , Boberg, K. M. , Bowlus, C. L. , Bragazzi, M. C. &55 mehr Carbone, M., Chazouillères, O., Cheung, A., Dalekos, G., Eaton, J., Eksteen, B., Ellinghaus, D., Färkkilä, M., Festen, E. A. M., Floreani, A., Franceschet, I., Gotthardt, D. N., Hirschfield, G. M., Hoek, B. V., Holm, K., Hohenester, S., Hov, J. R., Imhann, F., Invernizzi, P., Juran, B. D., Lenzen, H., Lieb, W., Liu, J. Z., Marschall, H-U., Marzioni, M., Melum, E., Milkiewicz, P., Müller, T., Pares, A., Rupp, C., Rust, C., Sandford, R. N., Schramm, C., Schreiber, S., Schrumpf, E., Silverberg, M. S., Srivastava, B., Sterneck, M., Teufel, A., Vallier, L., Verheij, J., Vila, A. V., Vries, B. D., Zachou, K., Chapman, R. W., Manns, M. P., Pinzani, M., Rushbrook, S. M., Lazaridis, K. N., Franke, A., Anderson, C. A., Karlsen, T. H., Ponsioen, C. Y., Weersma, R. K. & International PSC Study Group, The UK PSC Consortium 08.2018 in : GUT. 67, 8, S. 1517-1524
  • Geoepidemiology and (epi-)genetics in primary biliary cholangitis. Rosa R, Cristoferi L, Tanaka A, Invernizzi P. Best Pract Res Clin Gastroenterol. 2018 Jun - Aug;34-35:11-15. doi: 10.1016/j.bpg.2018.05.011. Epub 2018 May 16. Review.
  • Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. Terziroli Beretta-Piccoli B, Stirnimann G, Cerny A, Semela D, Hessler R, Helbling B, Stickel F, Kalid-de Bakker C, Bihl F, Giostra E, Filipowicz Sinnreich M, Oneta C, Baserga A, Invernizzi P, Carbone M, Mertens J. Clin Rev Allergy Immunol. 2018 Apr;54(2):295-306. doi: 10.1007/s12016-017-8656-x
  • Harris T, Sandford R, de Coninck B, Devuyst O, Drenth JPH, Ecder T, Kent A, Gansevoort RT, Górriz JL, Ong ACM, Pirson Y, Torres VE, Budde K, Clément D, Derchi LE, Eleftheroudi M, Levtchenko E, Peters D, Van Poppel H, Vanholder R. European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. NEPHROLOGY DIALYSIS TRANSPLANTATION Volume: 33 Issue: 4 Pages: 563-573 Published: APR 2018By:
  • Holz R, Kremer AE, Lütjohann D, Wasmuth HE, Lammert F, Krawczyk M. Can genetic testing guide the therapy of cholestatic pruritus? A case of benign recurrent intrahepatic cholestasis type 2 with severe nasobiliary drainage-refractory itch. Hepatol Commun. 2018 Jan 10;2(2):152-154. doi: 10.1002/hep4.1144. eCollection 2018 Feb. PubMed PMID: 29404523; PubMed Central PMCID: PMC5796322.
  • Individualizing Care: Management Beyond Medical Therapy. Cristoferi L, Nardi A, Invernizzi P, Mells G, Carbone M. Clin Liver Dis. 2018 Aug;22(3):545-561. doi: 10.1016/j.cld.2018.03.006. Review.
  • Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom Dyson, J. K., Wong, L. L., Bigirumurame, T., Hirschfield, G. M., Kendrick, S., Oo, Y. H., Lohse, A. W., Heneghan, M. A., Jones, D. E. J. & UK-AIH Consortium 11.2018 in : ALIMENT PHARM THER. 48, 9, S. 951-960
  • Janik MK, Wunsch E, Raszeja-Wyszomirska J, Moskwa M, Kruk B, Krawczyk M, Milkiewicz P. Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: A prospective, single-centre study. Liver Int. 2019 Jan;39(1):215-221. doi: 10.1111/liv.13960. Epub 2018 Sep 29. PubMed PMID: 30204306.
  • Jung F, Cazzagon N, Vettorazzi E, Corpechot C, Chazouilleres O, Arrivé L, Lohse AW, Schramm C, Ehlken H. Rate of Spleen Length Progression is a Marker of Outcome in Patients with Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2019 Jan 4. pii: S1542-3565(19)30006-0. doi: 10.1016/j.cgh.2018.12.033. [Epub ahead of print] PubMed PMID: 30616025.
  • Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Marschall HU, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones D; Obeticholic Acid PBC Monotherapy Study Group. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018 May;67(5):1890-1902. doi: 10.1002/hep.29569. Epub 2018 Jan 29. PubMed PMID: 29023915; PubMed Central PMCID: PMC5947631.
  • Kruk B, Liebe R, Milkiewicz M, Wunsch E, Raszeja-Wyszomirska J, Lammert F, Milkiewicz P, Krawczyk M. PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC. PLoS One. 2018 Aug 30;13(8):e0202942. doi: 10.1371/journal.pone.0202942. eCollection 2018. PubMed PMID: 30161167; PubMed Central PMCID: PMC6117000.
  • Krupa Ł, Staroń R, Pająk J, Lammert F, Krawczyk M, Gutkowski K. Secondary systemic amyloidosis diagnosed by endoscopic ultrasound-guided liver biopsy. J Gastrointestin Liver Dis. 2018 Mar;27(1):101-102. doi:10.15403/jgld.2014.1121.271.kru. PubMed PMID: 29557423.
  • Lemoinne S, Pares A, Reig A, Ben Belkacem K, Kemgang Fankem AD, Gaouar F, Poupon R, Housset C, Corpechot C, Chazouillères O. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. Clin Res Hepatol Gastroenterol. 2018 Dec;42(6):521-528. doi: 10.1016/j.clinre.2018.06.009. Epub 2018 Aug 9. PubMed PMID: 30100231.
  • Marschall HU. Ensuring timely treatment of patients with primary biliary cholangitis. Lancet Gastroenterol Hepatol. 2018 Sep;3(9):591-593. doi:10.1016/S2468-1253(18)30177-8. Epub 2018 Jul 13. PubMed PMID: 30017647.
  • Meijer, E., F. W. Visser, R. M. M. van Aerts, C. J. Blijdorp, N. F. Casteleijn, H. M. A. D'Agnolo, S. E. I. Dekker, J. P. H. Drenth, J. W. de Fijter, M. D. A. van Gastel, T. J. Gevers, M. A. Lantinga, M. Losekoot, A. L. Messchendorp, M. K. Neijenhuis, M. J. Pena, D. J. M. Peters, M. Salih, D. Soonawala, E. M. Spithoven, J. F. Wetzels, R. Zietse and R. T. Gansevoort (2018). "Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial." Jama 320(19): 2010-2019.
  • Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group. Hepatology. 2018 May;67(5):1920-1930. doi: 10.1002/hep.29717. Epub 2018 Apr 6
  • Mutations in the novel gene FOPV are associated with familial autosomal dominant and non-familial obliterative portal venopathy. Besmond C, Valla D, Hubert L, Poirier K, Grosse B, Guettier C, Bernard O, Gonzales E, Jacquemin E. Liver Int. 2018 Feb;38(2):358-364. doi: 10.1111/liv.13547. Epub 2017 Sep 12.
  • Neijenhuis, M. K., W. Kievit, S. M. Verheesen, H. M. D'Agnolo, T. J. Gevers and J. P. Drenth (2018). "Impact of liver volume on polycystic liver disease-related symptoms and quality of life." United European Gastroenterol J 6(1): 81-88.
  • Neijenhuis, M., T. J. G. Gevers, T. D. Atwell, T. J. Gunneson, A. C. Schimek, W. Kievit, J. P. H. Drenth and P. S. Kamath (2018). "Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites." Am J Gastroenterol 113(4): 567-575.
  • Nevens F. PBC-transplantation and disease recurrence. Best Pract Res Clin Gastroenterol. 2018 Jun - Aug;34-35:107-111. doi: 10.1016/j.bpg.2018.09.001. Epub 2018 Sep 11. Review
  • NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. de Graaf KL, Lapeyre G, Guilhot F, Ferlin W, Curbishley SM, Carbone M, Richardson P, Moreea S, McCune CA, Ryder SD, Chapman RW, Floreani A, Jones DE, de Min C, Adams DH, Invernizzi P. Hepatol Commun. 2018 Mar 23;2(5):492-503. doi: 10.1002/hep4.1170. eCollection 2018 May
  • Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome. Andrade F, Shukla A, Bureau C, Senzolo M, D'Alteroche L, Heurgué A, Garcia-Pagan JC, Turon F, Oberti F, Tripathi D, Roux O, Ceccaldi PF, de Raucourt E, Payancé A, Valla D, Plessier A, Rautou PE; VALDIG investigators. J Hepatol. 2018 Dec;69(6):1242-1249. doi: 10.1016/j.jhep.2018.08.007. Epub 2018 Aug 21.
  • Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J, Bernuzzi F, Cardinale V, Ainsworth HF, Heneghan MA, Thorburn D, Bathgate A, Jones R, Neuberger JM, Battezzati PM, Zuin M, Taylor-Robinson S, Donato MF, Kirby J, Mitchell-Thain R, Floreani A, Sampaziotis F, Muratori L, Alvaro D, Marzioni M, Miele L, Marra F, Giannini E, Gaudio E, Ronca V, Bonato G, Cristoferi L, Malinverno F, Gerussi A, Stocken DD, Cordell HJ, Hirschfield GM, Alexander GJ, Sandford RN, Jones DE, Invernizzi P, Mells GF; Italian PBC Study Group and the UK–PBC Consortium. Lancet Gastroenterol Hepatol. 2018 Sep;3(9):626-634. doi: 10.1016/S2468-1253(18)30163-8. Epub 2018 Jul 13
  • Primary sclerosing cholangitis. Dyson, J. K., Beuers, U., Jones, D. E. J., Lohse, A. W. & Hudson, M. 23.06.2018 in : LANCET. 391, 10139, S. 2547-2559
  • Prognostic models in primary biliary cholangitis. Cristoferi L, Nardi A, Ronca V, Invernizzi P, Mells G, Carbone M. J Autoimmun. 2018 Dec;95:171-178. doi: 10.1016/j.jaut.2018.10.024. Epub 2018 Nov 9. Review.
  • Recommendations on the use of magnetic resonance imaging for collaborative multicenter studies in PSC Ringe, K. I., Grigoriadis, A., Halibasic, E., Wacker, F., Manns, M. P., Schramm, C., Lenzen, H. & MRI working group of the IPSCSG 17.09.2018 in : HEPATOLOGY.
  • Reichert MC, Lammert F. ABCB4 Gene Aberrations in Human Liver Disease: An Evolving Spectrum. Semin Liver Dis. 2018 Nov;38(4):299-307. doi: 10.1055/s-0038-1667299. Epub 2018 Oct 24. Review. PubMed PMID: 30357767.
  • Risk stratification and prognostic modelling in primary biliary cholangitis. Goet JC, Harms MH, Carbone M, Hansen BE. Best Pract Res Clin Gastroenterol. 2018 Jun - Aug;34-35:95-106. doi: 10.1016/j.bpg.2018.06.006. Epub 2018 Jun 18. Review
  • Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis. Banales JM, Iñarrairaegui M, Arbelaiz A, Milkiewicz P, Muntane J, Muñoz-Bellvis L, La Casta A, Gonzalez LM, Arretxe E, Alonso C, Martínez-Arranz I, Lapitz A, Santos-Laso A, Avila MA, Martínez-Chantar ML, Bujanda L, Marin JJG, Sangro B, Macias RIR. Hepatology. 2018 Oct 16. doi: 10.1002/hep.30319. [Epub ahead of print]
  • Sturm E, Verkade HJ. Disorders of the intrahepatic bile ducts. In: Walker WA, Hamilton JR, Watkins JB, Durie PR, Walker-Smith JA, eds. Pediatric Gastrointestinal Disease. BC Decker, Hamilton; 2018, 6th edition.
  • Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers. Bossen L, Gerussi A, Lygoura V, Mells GF, Carbone M, Invernizzi P Autoimmun Rev. 2018 Sep;17(9):854-865. doi: 10.1016/j.autrev.2018.02.013. Epub 2018 Jul 11. Review
  • The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis. Santamaría E, Rodríguez-Ortigosa CM, Uriarte I, Latasa MU, Urtasun R, Alvarez-Sola G, Bárcena-Varela M, Colyn L, Arcelus S, Jiménez M, Deutschmann K, Peleteiro-Vigil A, Gómez-Cambronero J, Milkiewicz M, Milkiewicz P, Sangro B, Keitel V, Monte MJ, Marin JJ, Fernández-Barrena MG, Ávila MA, Berasain C.Hepatology. 2018 Nov 8. doi: 10.1002/hep.30348. [Epub ahead of print]
  • The immunobiology of female predominance in primary biliary cholangitis. Gerussi A, Cristoferi L, Carbone M, Asselta R, Invernizzi P. J Autoimmun. 2018 Dec;95:124-132. doi: 10.1016/j.jaut.2018.10.015. Epub 2018 Oct 25. Review.
  • Transient portal vein thrombosis in liver cirrhosis. Qi X, Guo X, Yoshida EM, Méndez-Sánchez N, De Stefano V, Tacke F, Mancuso A, Sugawara Y, Yang SS, Teschke R, Arora A, Valla DC. BMC Med. 2018 Jun 5;16(1):83. doi: 10.1186/s12916-018-1069-8. Review. PMID: 29871683
  • Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2-/- mice and human primary sclerosing cholangitis. Meng F, Kennedy L, Hargrove L, Demieville J, Jones H, Madeka T, Karstens A, Chappell K, Alpini G, Sybenga A, Invernizzi P, Bernuzzi F, DeMorrow S, Francis H. Lab Invest. 2018 Nov;98(11):1465-1477. doi: 10.1038/s41374-018-0101-0. Epub 2018 Aug 24
  • van Aerts RMM, Kievit W, de Jong ME, Ahn C, Bañales JM, Reiterová J, Nevens F, Drenth JPH. Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry. Liver Int. 2018 Sep 17.
  • van Aerts, R. M. M., M. Kolkman, W. Kievit, T. J. G. Gevers, F. Nevens and J. P. H. Drenth (2018). "Drug holiday in patients with polycystic liver disease treated with somatostatin analogues." Therap Adv Gastroenterol 11: 1756284818804784.
  • van de Laarschot, L. F. M. and J. P. H. Drenth (2018). "Genetics and mechanisms of hepatic cystogenesis." Biochim Biophys Acta 1864(4 Pt B): 1491-1497.
  • Wijnands, T. F. M., T. J. G. Gevers, M. A. Lantinga, R. H. Te Morsche, L. J. Schultze Kool and J. P. H. Drenth (2018). "Pasireotide does not improve efficacy of aspiration sclerotherapy in patients with large hepatic cysts, a randomized controlled trial." Eur Radiol 28(6): 2682-2689.
  • Wijnands, T. F., B. Schoenemeier, A. Potthoff, T. J. Gevers, H. Groenewoud, M. J. Gebel, K. Rifai, M. P. Manns and J. P. Drenth (2018). "Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts." United European Gastroenterol J 6(6): 919-925.
  • Wunsch E, Raszeja-Wyszomirska J, Barbier O, Milkiewicz M, Krawczyk M, Milkiewicz P. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. J Gastrointestin Liver Dis. 2018 Sep;27(3):273-279. doi: 10.15403/jgld.2014.1121.273.icz. PubMed PMID: 30240471.
  • Zimmer V, Bohle RM, Weber SN, Lammert F, Jüngst C. Benign recurrent intrahepatic cholestasis (BRIC)-like episode associated with ATP8B1 variation underlying protracted cholestatic course of acute hepatitis E virus infection. Dig Liver Dis. 2018 Feb;50(2):206-207. doi: 10.1016/j.dld.2017.10.022. Epub 2017 Nov 8. PubMed PMID: 29191380.

2017

  • 24. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Ji, S-G. , Juran, B. D. , Mucha, S. , Folseraas, T. , Jostins, L. , Melum, E. , Kumasaka, N. , Atkinson, E. J. , Schlicht, E. M. , Liu, J. Z. , Shah, T. , Gutierrez-Achury, J. , Boberg, K. M. , Bergquist, A. , Vermeire, S. , Eksteen, B. , Durie, P. R. , Farkkila, M. , Müller, T. , Schramm, C. &51 mehr Sterneck, M., Weismüller, T. J., Gotthardt, D. N., Ellinghaus, D., Braun, F., Teufel, A., Laudes, M., Lieb, W., Jacobs, G., Beuers, U., Weersma, R. K., Wijmenga, C., Marschall, H-U., Milkiewicz, P., Pares, A., Kontula, K., Chazouillères, O., Invernizzi, P., Goode, E., Spiess, K., Moore, C., Sambrook, J., Ouwehand, W. H., Roberts, D. J., Danesh, J., Floreani, A., Gulamhusein, A. F., Eaton, J. E., Schreiber, S., Coltescu, C., Bowlus, C. L., Luketic, V. A., Odin, J. A., Chopra, K. B., Kowdley, K. V., Chalasani, N., Manns, M. P., Srivastava, B., Mells, G., Sandford, R. N., Alexander, G., Gaffney, D. J., Chapman, R. W., Hirschfield, G. M., de Andrade, M., Rushbrook, S. M., Franke, A., Karlsen, T. H., Lazaridis, K. N., Anderson, C. A. & UK-PSC Consortium 02.2017 in : NAT GENET. 49, 2, S. 269-273
  • 87. The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Shuai Z, Wang J, Badamagunta M, Choi J, Yang G, Zhang W, Kenny TP, Guggenheim K, Kurth MJ, Ansari AA, Voss J, Coppel RL, Invernizzi P, Leung PSC, Gershwin ME. Hepatology. 2017 May;65(5):1670-1682. doi: 10.1002/hep.29059. Epub 2017 Mar 3
  • A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation. Zhang H, Lian M, Zhang J, Bian Z, Tang R, Miao Q, Peng Y, Fang J, You Z, Invernizzi P, Wang Q, Gershwin ME, Ma X. Hepatology. 2018 Jan;67(1):232-246. doi: 10.1002/hep.29418. Epub 2017 Nov 17
  • Bolier R, de Vries ES, Parés A, Helder J, Kemper EM, Zwinderman K, Elferink RPO, Beuers U; Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials. 2017 May 23;18(1):230. doi: 10.1186/s13063-017-1966-8. PubMed PMID: 28535810; PubMedCentral PMCID: PMC5442649.
  • Borssén ÅD, Palmqvist R, Kechagias S, Marschall HU, Bergquist A, Rorsman F, Weiland O, Verbaan H, Nyhlin N, Nilsson E, Werner M. Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis: A cohortstudy. Medicine (Baltimore). 2017 Aug;96(34):e7708. doi: 10.1097/MD.0000000000007708. PubMed PMID: 28834875; PubMed Central PMCID: PMC5571997.
  • Danielsson Borssén Å, Marschall HU, Bergquist A, Rorsman F, Weiland O, Kechagias S, Nyhlin N, Verbaan H, Nilsson E, Werner M. Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. Scand J Gastroenterol. 2017 Sep;52(9):1022-1028. doi: 10.1080/00365521.2017.1335772. Epub 2017 May 31. PubMed PMID: 28562110.
  • De Gottardi A; Trebicka J; Klinger C; Plessier A; Seijo S; Terziroli B; Magenta L; Semela D; Buscarini E; Langlet P; Görtzen J; Puente A; Müllhaupt B; Navascuès C; Nery F; Deltenre P; Turon F; Engelmann C; Arya R; Caca K; Peck-Radosavljevic M; Leebeek FW; Valla D; Garcia-Pagan JC; VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017 May;37(5):694-699. doi: 10.1111/liv.13285.
  • de Vries EMG, Färkkilä M, Milkiewicz P, Hov JR, Eksteen B, Thorburn D, Chazouillères O, Pares A, Nygård S, Gilja OH, Wunsch E, Invernizzi P, Carbone M, Bernuzzi F, Boberg KM, Røsjø H, Rosenberg W, Beuers UH, Ponsioen CY, Karlsen TH, Vesterhus M. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. Liver Int. 2017 Oct;37(10):1554-1561. doi: 10.1111/liv.13402. Epub 2017 Apr 13. PubMed PMID: 28267887.
  • Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. Raggi C, Gammella E, Correnti M, Buratti P, Forti E, Andersen JB, Alpini G, Glaser S, Alvaro D, Invernizzi P, Cairo G, Recalcati S. Sci Rep. 2017 Dec 15;7(1):17667. doi: 10.1038/s41598-017-17804-1
  • EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. - Journal Of hepatology 2017 vol 67: 145-172. http://www.easl.eu/medias/cpg/Primary%20biliary%20cholangitis/English-report.pdf
  • Efe C, Hagström H, Ytting H, Bhanji RA, Müller NF, Wang Q, Purnak T, Muratori L, Werner M, Marschall HU, Muratori P, Gunşar F, Klintman D, Parés A, Heurgué-Berlot A, Schiano TD, Cengiz M, May-Sien Tana M, Ma X, Montano-Loza AJ, Berg T, Verma S, Larsen FS, Ozaslan E, Heneghan MA, Yoshida EM, Wahlin S. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2017 Dec;15(12):1950-1956.e1. doi: 10.1016/j.cgh.2017.06.001. Epub 2017 Jun 8. PubMed PMID: 28603052.
  • Expert clinical management of autoimmune hepatitis in the real world. Liberal, R., de Boer, Y. S., Andrade, R. J., Bouma, G., Dalekos, G. N., Floreani, A., Gleeson, D., Hirschfield, G. M., Invernizzi, P., Lenzi, M., Lohse, A. W., Macedo, G., Milkiewicz, P., Terziroli, B., van Hoek, B., Vierling, J. M., Heneghan, M. A. & International Autoimmune Hepatitis Group (IAIHG) 03.2017 in : ALIMENT PHARM THER. 45, 5, S. 723-732
  • Felux J, Sturm E, Busch A, Zerabruck E, Graepler F, Stüker D, Manger A, Kirschner HJ, Blumenstock G, Malek NP, Goetz M. ERCP in infants, children and adolescents is feasible and safe: results from a tertiary care center. United European Gastroenterol J. 2017 Nov;5(7):1024-1029.
  • From pathogenesis to novel therapies in the treatment of primary biliary cholangitis. Ronca V, Carbone M, Bernuzzi F, Malinverno F, Mousa HS, Gershwin ME, Invernizzi P. Expert Rev Clin Immunol. 2017 Dec;13(12):1121-1131. doi: 10.1080/1744666X.2017.1391093. Epub 2017 Nov 9. Review.
  • Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Fawaz R1, Baumann U, Ekong U, Fischler B, Hadzic N, Mack CL, McLin VA, Molleston JP, Neimark E, Ng VL, Karpen SJ. J Pediatr Gastroenterol Nutr. 2017 Jan;64(1):154-168. doi: 10.1097/MPG.0000000000001334.
  • Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. Am J Gastroenterol. 2018 Feb;113(2):254-264. doi: 10.1038/ajg.2017.440. Epub 2017 Dec 12. PubMed PMID: 29231188.
  • Hartleif S, Schumm M, Döring M, Mezger M, Lang P, Dahlke MH, Riethmüller J, Königsrainer A, Handgretinger R, Nadalin S, Sturm E. Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study. Stem Cells Int. 2017;2017:2352954.
  • Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2-/- mice. Hall C, Ehrlich L, Meng F, Invernizzi P, Bernuzzi F, Lairmore TC, Alpini G, Glaser S. J Surg Res. 2017 Sep;217:160-169. doi: 10.1016/j.jss.2017.05.020. Epub 2017 May 11
  • Jüngst C, Stadlbauer V, Reichert MC, Zimmer V, Weber SN, Ofner-Ziegenfuß L, Voigtländer T, Spindelböck W, Fickert P, Kirchner GI, Lammert F, Lankisch TO, Krawczyk M. NOD2 gene variants confer risk for secondary sclerosing cholangitis in critically ill patients. Sci Rep. 2017 Aug 1;7(1):7026. doi: 10.1038/s41598-017-06268-y. PubMed PMID: 28765628; PubMed Central PMCID: PMC5539147.
  • Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b. Kyritsi K, Meng F, Zhou T, Wu N, Venter J, Francis H, Kennedy L, Onori P, Franchitto A, Bernuzzi F, Invernizzi P, McDaniel K, Mancinelli R, Alvaro D, Gaudio E, Alpini G, Glaser S. Am J Pathol. 2017 Jul;187(7):1551-1565. doi: 10.1016/j.ajpath.2017.03.013. Epub 2017 May 12
  • Krawczyk M, Lammert F. Search for Genetic Modifiers of PSC: Time to Increase the Number of Needles in the Haystack. Ann Hepatol. 2017 November-December,;16(6):830-831. doi: 10.5604/01.3001.0010.5271. PubMed PMID: 29055915.
  • Krawczyk M, Ligocka J, Ligocki M, Raszeja-Wyszomirska J, Milkiewicz M, Szparecki G, Ilczuk T, Górnicka B, Zieniewicz K, Krawczyk M, Lammert F, Milkiewicz P. Does transient elastography correlate with liver fibrosis in patients with PSC? Laennec score-based analysis of explanted livers. Scand J Gastroenterol. 2017 Dec;52(12):1407-1412. doi: 10.1080/00365521.2017.1370009. Epub 2017 Aug 29. PubMed PMID: 28851259.
  • Kuś A, Arłukowicz-Grabowska M, Szymański K, Wunsch E, Milkiewicz M, Płoski R, Shums Z, Norman GL, Milkiewicz P, Bednarczuk T, Krawczyk M. Genetic Risk Factors for Autoimmune Thyroid Disease might Affect the Susceptibility to and Modulatethe Progression of Primary Biliary Cholangitis. J Gastrointestin Liver Dis. 2017 Sep;26(3):245-252. doi: 10.15403/jgld.2014.1121.263.kus. PubMed PMID: 28922436.
  • Liver Int. 2017 May;37(5):694-699. Epub 2016 Nov 19. Antithrombotic treatment with directacting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. De Gottardi A1, Trebicka J2, Klinger C3, Plessier A4, S
  • Molinaro A, Marschall HU. Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications? Curr Hepatol Rep. 2017;16(2):119-123. doi: 10.1007/s11901-017-0345-y. Epub 2017 Apr 27. Review. PubMed PMID: 28706773; PubMed Central PMCID: PMC5486599.
  • norUrsodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis Fickert, P. , Hirschfield, G. M. , Denk, G. , Marschall, H-U. , Altorjay, I. , Färkkilä, M. , Schramm, C. , Spengler, U. , Chapman, R. W. , Bergquist, A. , Schrumpf, E. , Nevens, F. , Trivedi, P. J. , Reiter, F. P. , Tornai, I. , Halilbasic, E. , Greinwald, R. , Pröls, M. , Manns, M. P. , Trauner, M. &1 mehr European PSC norUDCA Study Group 09.2017 in : J HEPATOL. 67, 3, S. 549-558
  • Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. Carbone M, Cristoferi L, Cortesi PA, Rota M, Ciaccio A, Okolicsanyi S, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Belli LS, Munari LM, Mantovani L, Strazzabosco M. Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1415-1422. doi: 10.1016/j.bbadis.2017.08.025. Epub 2017 Aug 24
  • Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis Weismüller, T. J. , Trivedi, P. J. , Bergquist, A. , Imam, M. , Lenzen, H. , Ponsioen, C. Y. , Holm, K. , Gotthardt, D. , Färkkilä, M. A. , Marschall, H-U. , Thorburn, D. , Weersma, R. K. , Fevery, J. , Mueller, T. , Chazouillères, O. , Schulze, K. , Lazaridis, K. N. , Almer, S. , Pereira, S. P. , Levy, C. &40 mehr Mason, A. L., Naess, S., Bowlus, C. L., Floreani, A., Halilbasic, E., Yimam, K. K., Milkiewicz, P., Beuers, U., Huynh, D. K., Pares, A., Manser, C. N., Dalekos, G. N., Eksteen, B., Invernizzi, P., Berg, C. P., Kirchner, G. I., Sarrazin, C., Zimmer, V., Fabris, L., Braun, F., Marzioni, M., Juran, B. D., Said, K., Rupp, C., Jokelainen, K., Benito de Valle, M., Saffioti, F., Cheung, A., Trauner, M., Schramm, C., Chapman, R. W., Karlsen, T. H., Schrumpf, E., Strassburg, C-P., Manns, M. P., Lindor, K. D., Hirschfield, G. M., Hansen, B. E., Boberg, K. M. & International PSC Study Group 06.2017 in : GASTROENTEROLOGY. 152, 8, S. 1975-1984.e8
  • Poisson J; Plessier A; Kiladjian JJ; Turon F; Cassinat B; Andreoli A; De Raucourt E; Goria O; Zekrini K; Bureau C; Lorre F; Cervantes F; Colomer D; Durand F; Garcia-Pagan JC; Casadevall N; Valla DC; Rautou PE; Marzac C; French national network for vascular liver diseases. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. J Hepatol. 2017 Sep;67(3):501-507. doi: 10.1016/j.jhep.2017.04.021.
  • Primary Biliary Cholangitis Associated with Skin Disorders: A Case Report and Review of the Literature. Terziroli Beretta-Piccoli B, Guillod C, Marsteller I, Blum R, Mazzucchelli L, Mondino C, Invernizzi P, Gershwin ME, Mainetti C. Arch Immunol Ther Exp (Warsz). 2017 Aug;65(4):299-309. doi: 10.1007/s00005-016-0448-0. Epub 2017 Jan 25. Review
  • Primary Biliary Cholangitis: advances in management and treatment of the disease. Invernizzi P, Floreani A, Carbone M, Marzioni M, Craxi A, Muratori L, Vespasiani Gentilucci U, Gardini I, Gasbarrini A, Kruger P, Mennini FS, Ronco V, Lanati E, Canonico PL, Alvaro D. Dig Liver Dis. 2017 Aug;49(8):841-846. doi: 10.1016/j.dld.2017.05.001. Epub 2017 May 8
  • Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation. Wu N, Meng F, Zhou T, Han Y, Kennedy L, Venter J, Francis H, DeMorrow S, Onori P, Invernizzi P, Bernuzzi F, Mancinelli R, Gaudio E, Franchitto A, Glaser S, Alpini G. FASEB J. 2017 Oct;31(10):4305-4324. doi: 10.1096/fj.201700097R. Epub 2017 Jun 20
  • Recommendations on the use of MRI in PSC-A position statement from the International PSC study group. Schramm, C., Eaton, J. E., Ringe, K. I., Venkatesh, S., Yamamura, J. & MRI working group of the IPSCSG 11.2017 in : HEPATOLOGY. 66, 5, S. 1675-1688
  • Reichert MC, Hall RA, Krawczyk M, Lammert F. Genetic determinants of cholangiopathies: Molecular and systems genetics. Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1484-1490. doi: 10.1016/j.bbadis.2017.07.029. Epub 2017 Jul 27. Review. PubMed PMID: 28757171.
  • Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Aabakken, L., Karlsen, T. H., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J-M., Färkkilä, M., Fickert, P., Hirschfield, G. M., Laghi, A., Marzioni, M., Fernandez, M., Pereira, S. P., Pohl, J., Poley, J-W., Ponsioen, C. Y., Schramm, C., Swahn, F., Tringali, A. & Hassan, C. 06.2017 in : ENDOSCOPY. 49, 6, S. 588-608
  • Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Arbelaiz A, Azkargorta M, Krawczyk M, Santos-Laso A, Lapitz A, Perugorria MJ, Erice O, Gonzalez E, Jimenez-Agüero R, Lacasta A, Ibarra C, Sanchez-Campos A, Jimeno JP, Lammert F, Milkiewicz P, Marzioni M, Macias RIR, Marin JJG, Patel T, Gores GJ, Martinez I, Elortza F, Falcon-Perez JM, Bujanda L, Banales JM. Hepatology. 2017 Oct;66(4):1125-1143. doi: 10.1002/hep.29291. Epub 2017 Aug 26.
  • Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. Terziroli Beretta-Piccoli B, Invernizzi P, Gershwin ME, Mainetti C. Clin Rev Allergy Immunol. 2017 Dec;53(3):394-412. doi: 10.1007/s12016-017-8649-9. Review
  • Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. Wan Y, Meng F, Wu N, Zhou T, Venter J, Francis H, Kennedy L, Glaser T, Bernuzzi F, Invernizzi P, Glaser S, Huang Q, Alpini G. Hepatology. 2017 Aug;66(2):528-541. doi: 10.1002/hep.29138. Epub 2017 Jun 19
  • Temmerman F, Chen F, Libbrecht L, Vander Elst I, Windmolders P, Feng Y, Ni Y, De Smedt H, Nevens F, van Pelt J. Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease. World J Gastroenterol. 2017 Aug 14;23(30):5499-5507. doi: 10.3748/wjg.v23.i30.5499

2016

  • Kelly D, Hartleif S, Verkade HJ, Rajanayagam J, McKiernan P, Mazariegos G, Hübscher S. Late Graft Hepatitis and Fibrosis in Pediatric Liver Allograft Recipients: Current Concepts and Future Developments Reply. Liver Transplantation, 23(3), 405-406. https://doi.org/10.1002/lt.24705
  • miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation. Ehrlich L, Hall C, Venter J, Dostal D, Bernuzzi F, Invernizzi P, Meng F, Trzeciakowski JP, Zhou T, Standeford H, Alpini G, Lairmore TC, Glaser S. Am J Pathol. 2017 Mar;187(3):570-580. doi: 10.1016/j.ajpath.2016.10.021. Epub 2017 Jan 11
  • The "gut microbiota" hypothesis in primary sclerosing cholangitis. Pontecorvi V, Carbone M, Invernizzi P. Ann Transl Med. 2016 Dec;4(24):512. doi: 10.21037/atm.2016.12.43